COVAX: Vaccine Supply/Allocation

Milestones :: Perspectives :: Research

 

COVAX: Vaccine Supply/Allocation

The COVAX Facility – FIRST ROUND OF ALLOCATION: ASTRA ZENECA/OXFORD VACCINE (manufactured by AstraZeneca & licensed and manufactured by Serum Institute of India)
Feb-May 2021 – last updated 2 March 2021
Introduction
Following from the publication of an interim distribution forecast, and based on current knowledge of supply availability, this first round of allocations provides information on provision of doses of the AstraZeneca(AZ)/Oxford vaccine to COVAX Facility participants, through May 2021.

This first round allocation outlines delivery of 237 million* doses of the AZ/Oxford vaccine – manufactured by AstraZeneca (AZ) & licensed and manufactured by Serum Institute of India (SII/AZ) – to 142 Facility participants.
[*This total does NOT include 5% of supply set aside for Humanitarian & Contingencies Buffer, not yet approved by Gavi Board]

This list will be updated by the end of the week to provide indicative timelines for the supply of these doses, split into Feb-March and April-May. These timelines are dependent on a variety of factors including national regulatory requirements, availability of supply, and fulfilment of other criteria such as validated national deployment and vaccination plans (NDVPs) from AMC participants, indemnification & liability agreements, and export and import authorisations.

Participants not listed have either exercised their rights to opt-out of this vaccine, wish to transfer allocated doses to AMC participants, are AMC-eligible but have not joined the AMC, have voluntarily delayed receipt of doses and communicated this intent ahead of allocation, or have not met financial requirements.

In addition to this first round of allocations, an exceptional distribution of 1.2 million doses of the Pfizer-BioNTech vaccine, anticipated for delivery in Q1 2021, was announced in early February. These doses are reflected in the table below, to provide a global overview of allocations to-date but are not part of this round of allocation.

Further allocation rounds for vaccines in the COVAX portfolio will be announced in due course.

 

Overview of the process
This first round of allocation took place as per the Fair allocation mechanism for COVID-19 vaccines through the COVAX Facility, which was developed by WHO in consultation with its Member States. This allocation framework for fair and equitable access to COVID-19 health products sets forth the criteria and approach to allocation of vaccines through the COVAX Facility.

The operationalization of the Framework, in accordance with the principles and provisions set forth in the document above, is performed by the Joint Allocation Taskforce (JAT), composed of staff from Gavi, the Vaccine Alliance and WHO, and the Independent Allocation Vaccine Group (IAVG). The main purpose of the IAVG is to make validation assessments of proposals for Vaccine Allocation Decisions (“VAD proposals”), which outline the volumes

of Vaccines that should be allocated to each country/economy participating under COVAX within a given time frame. The IAVG will consider VAD proposals prepared and submitted by the JAT.The IAVG met twice over 22 and 23 February 2021 to discuss this first round of allocation. All 12 IAVG members were present during both meetings, and therefore full quorum was achieved. The deliberations resulted in consensus and no divergent views were recorded on the proposed allocation.As is normal procedure, the IAVG allocation report was then validated by the WHO Deputy Director-General, and the decision was communicated tothe Office of the COVAX Facility, administered by Gavi.

 

TABLE: Allocations by Facility participant
Note: Table will be updated later this week to provide further information on anticipated supply timelines, split into February-March and April-May 2021.
[138 countries listed at title link above including an allocation for “non-UN Member States” of 1,125,600 doses of AZ]

 

::::::

Independent Allocation of Vaccines Group (IAVG)
[WHO webpage – accessed 6 Mar 2021]
One of the principal objectives of COVAX is to promote the fair and equitable allocation of COVID-19 vaccines that are procured or distributed through COVAX (the “Vaccines”) to countries and economies participating in COVAX. To achieve such objective, the mechanism through which Vaccines are allocated must be transparent and independent.

In this context, WHO, Gavi and CEPI (collectively, the “COVAX Partners”) support the establishment by WHO of an Independent Allocation of Vaccines Group (“IAVG”) pursuant to the WHO Regulations for Study and Scientific Groups, Collaborating Institutions and Other Mechanisms of Collaboration, and in accordance with these Terms of Reference. The IAVG is expected to play a pivotal role in the allocation of Vaccines under COVAX and to foster the independence of, and provide transparency into, the Vaccine-allocation decision-making under COVAX.

The main purpose of the IAVG is to make validation assessments of proposals for Vaccine Allocation Decisions (“VAD proposals”), which outline the volumes of Vaccines that should be allocated to each country/economy participating under COVAX within a given time frame. The IAVG will consider VAD proposals prepared and submitted by the Joint Allocation Taskforce (“JAT”), composed of WHO and Gavi staff.

The IAVG will have the following functions:
:: To review the VAD proposals submitted by the JAT and to request clarifications from the JAT when necessary;
:: To discuss with the JAT any adjustments to the VAD proposals considered necessary on the basis of IAVG’s critical assessment;
:: To make validation assessments of the VAD proposals, ensuring they are technically informed and based on the latest available data and evidence;
:: For each VAD proposal that is validated by the IAVG (hereinafter a “VAD”), to document and justify the validation of such VAD, including any adjustments made to the original VAD proposal submitted to the IAVG by the JAT;
:: To deliver the VADs to the WHO Deputy-Director General for further implementation by the JAT.

 

 

::::::

Independent Allocation of Vaccines Group (IAVG) Members – as of January 2021
Members
Professor Anna Mia Ekström
Dr Arlene King
Christopher Maher
Dr Narendra Kumar Arora
Dr Bruce G. Gellin
Dr Dafrossa Cyrily Lyimo
Professor Tjandra Aditama
Doctor Alejandro Cravioto
Maria Guevara
Dr Manica Balasegaram
Dr Poh Lian Lim
Dr Masahiko Hachiya

Terms of Reference: https://www.who.int/groups/iavg/terms-of-reference

::::::

Documents and reports
22 February 2021
Report of the Independent Allocation of Vaccines Group on the allocation of COVAX Facility secured vaccines: 22 February 2021
Overview
This report covers the first Allocation of Astra Zeneca vaccines produced at the following two sites for which WHO issued an Emergency Use Listing on 15 February 2021:
:: Serum Institute of India Pvt Ltd – COVID-19 Vaccine (ChAdOx1-S [recombinant]) – COVISHIELD™ – “SII AZ”
:: AstraZeneca/SKBio – COVID-19 Vaccine (ChAdOx1-S [recombinant]) – “AZ” …

::::::

Annexes
Report of the Joint Allocation Taskforce (JAT) on the distribution of COVAX Facility secured vaccines
COVAX FACILITY DISTRIBUTION of Astra Zeneca vaccines produced at two different sites: SK BIO in Republic of Korea and Serum Institute of India Pvt Ltd
Date of report 19 February 2021
Summary
:: The current distribution round is enclosing allocation of Astra Zeneca vaccines produced by two different manufacturers at the following two sites for which WHO issued an Emergency Use Listing on 15 February 2021:
>> Serum Institute of India Pvt Ltd – COVID-19 Vaccine (ChAdOx1-S [recombinant]) –
COVISHIELD™ – “SII AZ”
>>AstraZeneca/SKBio – COVID-19 Vaccine (ChAdOx1-S [recombinant]) – “AZ”

:: To date, 1,200,420 M doses of vaccine (Pfizer) have been allocated in a separate and distinct process (more details here) which was performed on 29 January 2021. These are referred to as “First Wave” doses. This was due to specificities pertaining to the Pfizer/ BioNTech deal as well as learning objectives. These doses are not included in this allocation round, however coverage reached in the participants that received these early doses are reflected in the allocation. To date no doses have been shipped to the 18 First Wave participants.

:: Supply needs for a COVAX Buffer are also factored in this allocation – with 5% of total available supply set aside. Further information is available in the Supply section below.

:: Considering the supply and demand characteristics, the overall number of doses to be distributed is 237,468,000 to 142 participants for the period January to May 2021 for AZ and SII AZ

:: Given the supply available (and the 2-dose regime) and the population of all the participants in this round, the average proportion of population covered in this round across countries is 5.52% (not weighted for population size)…